KROS: Is the Discount Book Value a Value Trap?

Takeda licensing drove a notable revenue surge for Keros in 2025, but the company reported zero product sales, concentrating revenue in non-recurring licensing income. Investors are balancing a discounted valuation against execution risk from volatile, licensing-driven revenue and lack of commercial product traction.

Analysis

Takeda licensing drove a notable revenue surge for Keros in 2025, but the company reported zero product sales, concentrating revenue in non-recurring licensing income. Investors are balancing a discounted valuation against execution risk from volatile, licensing-driven revenue and lack of commercial product traction.